What one share of Orchestra BioMed Holdings holds
We are a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies. We are led by a highly accomplished, multidisciplinary management team and a board of directors with extensive experience in all phases of therapeutic device development.
Orchestra BioMed Holdings’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.54 |
|---|---|
| Profit | −$1.00 |
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$0.99 |
| Cash and investments | $1.83 |
| Debt | $0.34 |
| Book value | $0.32 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2021 | — | −$0.02 | — | — | — | — |
| 2022 | $0.24 | −$2.24 | $0.04 | −$1.99 | — | −$0.34 |
| 2023 | $0.08 | −$1.48 | $0.00 | −$1.39 | — | $1.90 |
| 2024 | $0.07 | −$1.66 | $0.01 | −$1.38 | — | $0.86 |
| 2025 | $0.70 | −$1.11 | $0.01 | −$1.04 | — | $0.94 |
Common questions about Orchestra BioMed Holdings
How much does one share of Orchestra BioMed Holdings earn?
Over the last 12 months, Orchestra BioMed Holdings lost $1.00 for each share on $0.54 of sales.
Does Orchestra BioMed Holdings pay a dividend?
Orchestra BioMed Holdings didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Orchestra BioMed Holdings’s book value per share?
Orchestra BioMed Holdings’s book value is $0.32 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Orchestra BioMed Holdings have?
Each share of Orchestra BioMed Holdings has $1.83 of cash and investments and $0.34 of debt, as of June 30, 2026.
What is Orchestra BioMed Holdings’s free cash flow per share?
−$0.99 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Orchestra BioMed Holdings bought back shares?
Orchestra BioMed Holdings’s share count rose about 133% from 2021 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.